Malaysia MDA Introduces Two-Year Validity for Product Classification Letters

Malaysia’s Medical Device Authority (MDA) announced on November 11 2025, that Product Classification Letters will transition to a two-year validity model beginning May 1 2025. This update affects both newly issued and existing letters and reflects Malaysia’s ongoing effort to keep product determinations aligned with current regulatory expectations and evolving device standards.

If your organization requires support navigating these changes—such as classification assessments, renewal planning, or Malaysia medical device registration—contact Cisema for expert regulatory assistance.

New MDA Validity Requirement for Product Classification Letters

Under the new framework, Product Classification Letters issued on or after 31 May 2025 will carry a validity period of up to two years from the issuance date. This replaces the previous indefinite model and provides a clearer timeframe for ensuring that classification determinations reflect current regulatory conditions.

Furthermore, the introduction of a defined validity period also encourages more consistent documentation management. As a result, manufacturers and authorized representatives can more effectively synchronize regulatory planning, technical file updates, and submission strategies with Malaysia’s maturing regulatory landscape.

MDA Transitional Timelines for Classification Letter Validity

To support stakeholders as Malaysia moves toward a two-year validity model, the MDA outlined clear validity outcomes based on the original date of issuance. These timelines indicate when existing Product Classification Letters remain acceptable and when renewal or reapplication may be required to maintain compliance.

Validity timelines are as follows:

Date of Product Classification IssuanceValidity StatusBefore 1 January 2020No longer valid; a new application is required where a classification determination is still needed1 January 2020 – 31 December 2023No longer valid; a new application is required where a classification determination is still needed1 January 2024 – 31 May 2025Valid until 1 May 2027After 31 May 2025Valid for two years from the date of issuanceStarting 1 May 2027New Product Classification Letter framework fully in effect

In addition, the MDA confirmed that its earlier announcement dated April 1 2025 on the same topic is no longer applicable.

As the transition progresses, the MDA is expected to issue further guidance on renewal and reapplication procedures. Organizations preparing for upcoming registrations or product updates should monitor these updates closely to ensure that classification documentation remains valid at each stage of the regulatory process. Early planning will be particularly important for companies managing multiple device categories or preparing for modifications that may require refreshed classification determinations.

Impact and Recommendations for Manufacturers and Authorized Representatives

For overseas manufacturers and their Malaysian authorized representatives, the new validity framework affects regulatory planning, documentation management, and submission timing. A strategic, structured approach will help maintain uninterrupted access to the Malaysian market.

Adapting Malaysia Medical Device Registration Timelines

The introduction of expiry dates may affect planned registration activities or future submissions. Companies should review upcoming regulatory milestones—such as dossier updates, variant introductions, or renewals—to ensure that classification validity aligns with key deadlines and does not interrupt submission workflows.

Reviewing Existing MDA Classification Letters

Manufacturers holding older classification letters, particularly those issued before 2024, should confirm whether these documents remain valid for upcoming regulatory actions. In some cases, an early renewal or reapplication may be necessary to ensure alignment with the new framework.

Strengthening Internal Classification Validity Tracking

The shift to time-limited classification letters requires robust document management. Consequently, organizations should integrate expiry tracking and automated reminders into their regulatory systems, especially when overseeing multiple product families or risk classes. Proactive oversight will help avoid delays caused by lapsed documentation.

Supporting Compliance with Malaysia’s Updated Requirements

Malaysia’s transition to a two-year validity framework for product classification letters underscores the importance of structured regulatory planning and disciplined documentation oversight for companies operating in the market.

With a dedicated local office in Penang, Cisema provides on-the-ground regulatory insight and coordinated support to help organizations manage classification validity, prepare compliant submissions, and maintain uninterrupted Malaysian market access as the new framework takes effect.

For support with maintaining compliant classification documentation and securing Malaysian market access, get in touch with Cisema today.

Further Information

• Explore Cisema’s services for Malaysia medical device registration
• Read related news on registration fees for Class A medical devices
• Access our guide to Malaysia MDA registration

References

• Read the MDA original announcement: “Implementation of Validity Period for Product Classification Letter”